MIST
Closed
Milestone Pharmaceuticals Inc
1.88
-0.06 (-3.09%)
Last Update: 01 Jul 2025 23:21:00
Yesterday: 1.94
Day's Range: 1.88 - 1.97
Send
sign up or login to leave a comment!
When Written:
3.89
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for the treatment of cardiovascular diseases. The company was founded in 2005 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals is primarily focused on developing a novel therapy called etripamil, which is a calcium channel blocker that is administered intranasally. Etripamil is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), a type of arrhythmia that affects the heart's electrical system.
The company has completed multiple clinical trials for etripamil, including a Phase 3 trial that demonstrated the drug's effectiveness in terminating PSVT episodes. Milestone Pharmaceuticals plans to submit a New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) in 2021.
In addition to etripamil, Milestone Pharmaceuticals is also exploring other potential applications for its calcium channel blocker technology platform. The company has a pipeline of preclinical and clinical stage compounds targeting various cardiovascular diseases.
Milestone Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol "MIST."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Milestone Pharmaceuticals is primarily focused on developing a novel therapy called etripamil, which is a calcium channel blocker that is administered intranasally. Etripamil is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), a type of arrhythmia that affects the heart's electrical system.
The company has completed multiple clinical trials for etripamil, including a Phase 3 trial that demonstrated the drug's effectiveness in terminating PSVT episodes. Milestone Pharmaceuticals plans to submit a New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) in 2021.
In addition to etripamil, Milestone Pharmaceuticals is also exploring other potential applications for its calcium channel blocker technology platform. The company has a pipeline of preclinical and clinical stage compounds targeting various cardiovascular diseases.
Milestone Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol "MIST."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
3.89
Milestone Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for cardiovascular and other diseases. The company's lead product candidate, etripamil, is a potential treatment for paroxysmal supraventricular tachycardia (PSVT), a type of heart rhythm disorder. Etripamil is an investigational, fast-acting, potent and selective calcium channel blocker delivered intranasally. Milestone Pharmaceuticals was founded in 2005 and is headquartered in Montreal, Canada. The company went public in May 2019 and is listed on the NASDAQ stock exchange under the symbol MIST.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!